Status:

ACTIVE_NOT_RECRUITING

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Lead Sponsor:

Christian von Buchwald

Collaborating Sponsors:

Naestved Hospital

Herlev Hospital

Conditions:

Oropharynx Cancer

Oropharynx Squamous Cell Carcinoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Oropharyngeal squamous cell carcinoma (OPSCC) is now the most frequently diagnosed head and neck cancer in Denmark which is mainly due to the increase of Human Papillomavirus (HPV). Patients with HPV-...

Detailed Description

The current study is performed as a nationwide randomized phase III study that aims to investigate the long-term functional outcomes after primary TORS and neck dissection vs. IMRT±concurrent chemothe...

Eligibility Criteria

Inclusion

  • 18 years or older
  • Able to provide informed consent
  • The Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2
  • Histologically confirmed oropharyngeal squamous cell carcinoma (exclusively palatine tonsils and base of tongue tumours) with known p16 status
  • Clinical tumour stage cT1-2 according to The Union for International Cancer Control (UICC), tumor (T), nodes (N), and metastases (M), (TNM) classification, 8th edition.
  • Clinical nodal stage cN0-1 according to UICC, TNM classification, 8th edition, however in p16 positive patients with unilateral metastasis, only a nodal metastasis up to a maximum of 4 cm in greatest diameter according to pre-operative imaging will be included.
  • Diagnostic imaging including computed tomography/magnetic resonance imaging (CT/MRI) performed within 14 days at time of randomization.
  • A tumour that is considered resectable according to MRI, clinical examination and/or ultrasound

Exclusion

  • Serious medical comorbidities or ECOG/WHO performance status \>2. Other contraindications to radiotherapy, chemotherapy or surgery
  • Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic
  • Distant metastasis
  • Clinically and radiologic signs of nodal extracapsular extension
  • Previous radiotherapy of the head and neck
  • Previous head and neck cancer
  • Significant trismus (maximum inter-incisal opening ≤ 35mm) \[46\]
  • Unable or unwilling to complete quality of life questionnaires
  • Posterior pharyngeal wall involvement
  • Pregnancy

Key Trial Info

Start Date :

March 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2029

Estimated Enrollment :

138 Patients enrolled

Trial Details

Trial ID

NCT04124198

Start Date

March 1 2019

End Date

December 1 2029

Last Update

December 31 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Aarhus University Hospital

Aarhus, Denmark

2

Copenhagen University Hospital Rigshospitalet

Copenhagen, Denmark

3

Odense University Hospital

Odense, Denmark